Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 200 shares, a decrease of 97.2% from the June 30th total of 7,045 shares. Based on an average daily trading volume, of 3,664 shares, the days-to-cover ratio is currently 0.1 days.

Clinuvel Pharmaceuticals Stock Performance

Clinuvel Pharmaceuticals stock remained flat at $7.35 during mid-day trading on Friday. The company’s stock had a trading volume of 36,763 shares, compared to its average volume of 3,028. The firm has a 50-day moving average price of $6.95 and a 200 day moving average price of $7.22. Clinuvel Pharmaceuticals has a one year low of $5.98 and a one year high of $9.00.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.